A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 6, Pages 160
Publisher
MDPI AG
Online
2018-05-28
DOI
10.3390/cancers10060160
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue.
- (2017) Saqib Razzaque et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Anne M Noonan et al. MOLECULAR THERAPY
- The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
- (2015) Devalingam Mahalingam et al. BMC CANCER
- Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
- (2015) Miguel A. Villalona-Calero et al. CANCER
- Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
- (2015) Douglas A. Rubinson et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
- (2014) Shashi A. Gujar et al. Frontiers in Oncology
- Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
- (2014) Jun Gong et al. Frontiers in Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
- (2013) J S Carew et al. Cell Death & Disease
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells
- (2012) Robert A. Adair et al. INTERNATIONAL JOURNAL OF CANCER
- Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples
- (2012) Gerard J Nuovo et al. MODERN PATHOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
- (2011) D Pan et al. BRITISH JOURNAL OF CANCER
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
- (2010) S. A. Gujar et al. MOLECULAR CANCER THERAPEUTICS
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus
- (2009) R. J. Prestwich et al. JOURNAL OF IMMUNOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
- (2008) L. Vidal et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now